MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis

BACKGROUND: Malignant ascites is a manifestation of end stage events in a variety of cancers and is associated with significant morbidity. Epigenetic modulators play a key role in cancer initiation and progression, among which histone deacetylases (HDACs) are considered as one of the most important...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Li, Wang, Dongyuan, Wei, Xiuqi, Liu, Chang, Xiao, Zhuanglong, Qian, Wei, Song, Yuhu, Hou, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783488/
https://www.ncbi.nlm.nih.gov/pubmed/35062876
http://dx.doi.org/10.1186/s12876-022-02101-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783488/
https://www.ncbi.nlm.nih.gov/pubmed/35062876
http://dx.doi.org/10.1186/s12876-022-02101-7

Ejemplares similares